Hillrom Reports Fiscal Fourth Quarter and Full-Year 2020 Financial Results
CHICAGO, Nov. 6, 2020 /PRNewswire/ -- Hillrom (NYSE: HRC) today announced financial results for its fiscal fourth quarter and full year ended September 30, 2020, and provided financial guidance for fiscal 2021.
For fiscal 2020, Hillrom reported GAAP earnings of $3.32 per diluted share compared to $2.25 per diluted share for fiscal 2019. Adjusted earnings of $5.53 per diluted share advanced 9 percent over the prior-year period and exceeded the company's projection of at least $5.40 per diluted share. For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.63 per diluted share compared to $0.41 per diluted share in the prior-year period. Adjusted earnings of $1.17 declined 31 percent compared to the prior-year period. Adjustments to reported earnings are detailed in the reconciliation schedules provided.
"We delivered on our fiscal fourth quarter expectations and achieved full-year adjusted earnings growth of 9 percent, in line with our original guidance range provided a year ago," said John Groetelaars, Hillrom president and CEO. "I'm very proud of our progress in 2020 toward our vision of Advancing Connected Care(TM), the extraordinary efforts to support peak customer demand, and steps we have taken to accelerate Hillrom's business transformation. With compelling value propositions across our diverse portfolio of connected solutions, we enter fiscal 2021 with encouraging recovery trends, confidence in our future growth prospects, and an unwavering commitment to enhancing shareholder value."
Fiscal 2020 and Fourth Quarter Financial Results
For fiscal 2020, worldwide revenue of $2.88 billion declined 1 percent on a reported and constant currency basis. Hillrom's core revenue advanced 3 percent for the year, including the contributions from acquisitions of approximately 200 basis points and approximately $180 million from one-time COVID-related purchases. Core revenue excludes foreign currency, divestitures, non-strategic assets the company exited and the Surgical Solutions international OEM business.
For the fiscal fourth quarter, worldwide revenue of $705 million, including approximately $35 million from one-time COVID-related purchases, declined 10 percent on a reported basis, or 11 percent on a constant currency basis. Hillrom's core revenue also declined 10 percent.
Fiscal Fourth Quarter Revenue by reporting segment:
-- Patient Support Systems revenue of $365 million declined 12 percent on a
reported basis, or 13 percent on a constant currency basis. Performance
reflects a challenging comparison to a record finish in the fourth
quarter of fiscal 2019, the impact of the COVID-19 peak demand for
med-surg and ICU bed systems in the fiscal third quarter, and nearly 30
percent sequential growth in the company's care communications
platforms. Partially offsetting U.S. weakness was strong international
growth of 17 percent on a constant currency basis, driven by elevated
demand for med-surg and ICU bed systems.
-- Front Line Care generated revenue of $260 million, an increase of 1
percent on a reported and constant currency basis driven by strong
demand for Welch Allyn vital signs and blood pressure monitoring
equipment, thermometry and non-invasive ventilators. Other product
categories, including physical assessment and diagnostic tools, declined
year-over-year in the U.S., but showed sequential improvement as
physician office visits returned to near pre-COVID levels.
-- Surgical Solutions revenue of $80 million declined 27 percent on a
reported basis, or 29 percent on a constant currency basis, reflecting
project delays, lower demand for surgical capital equipment, and the
2019 surgical consumables divestiture. Core revenue declined 27 percent.
2020 Highlights
Hillrom achieved significant milestones in 2020 aimed at realizing our vision of Advancing Connected Care, transforming the portfolio through innovation and M&A, and delivering sustainable value to shareholders. Highlights include:
-- Advancing category leadership with more than $570 million in new product
revenue during fiscal 2020. Contributing to this performance were
several innovative products, including the company's portfolio of smart
beds, vital signs monitoring devices, respiratory and vision products,
as well as Integrated Table Motion.
-- Rapidly developing and introducing more than a half-dozen new products,
many used in support of COVID-19 treatment, in the areas of care
communications, remote monitoring, respiratory health and surgical
workflow. These products expand the company's diverse portfolio and
include the following: Voalte® Extend(TM), a simplified mobile
communication platform that enables patient to caregiver communication;
the Extended Care Solution(TM), a connected remote vital signs
monitoring device that allows clinicians to shift care closer to home;
the Welch Allyn® Spot Vital Signs® 4400 next generation vital signs
device, which allows clinicians to remotely receive a complete set of
vitals, including SPO(2), temperature and blood pressure; two new
respiratory devices: Volara(TM) System for oscillation and lung
expansion therapy for use in both the acute and home settings, and
Synclara(TM) cough system to help clear mucus from upper airways; and
the PST 500, a precision surgical table that streamlines workflow in the
operating room.
-- Playing a critical role in the global fight against COVID-19 and
significantly increasing manufacturing capacity to meet elevated demand
for select products, including med-surg and ICU hospital beds,
non-invasive ventilators, patient monitoring devices, and certain
physical assessment tools and consumables.
-- Enhancing the company's portfolio of connected care solutions with three
acquisitions, Excel Medical Electronics LLC, Connecta Soft, and Videomed
S.r.l, bringing advanced, actionable point-of-care data to caregivers
and healthcare provider organizations.
-- Generating operating cash flow for the year of $482 million, reducing
debt by $147 million, and delivering significant value to shareholders
through increased dividends and share repurchases. During fiscal 2020,
Hillrom raised its dividend for the tenth consecutive year and returned
$129 million to shareholders through dividends and share repurchases.
The company's strong financial position is supported by a healthy
balance sheet, including $297 million in cash and cash equivalents, and
revolving credit facilities totaling $1.2 billion that can be used to
address capital needs as necessary.
-- Demonstrating commitment and support of local, national and
international communities with both monetary and product donations
totaling more than $6.5 million, including medical devices well-suited
for critical and intensive care environments to 25 U.S. hospitals
fighting COVID-19.
-- Promoting excellence in the workplace and commitment to diversity,
inclusion and belonging initiatives as the recipient of multiple awards
and recognitions, including the Ecovadis Gold Award for Sustainable
Procurement, Great Place To Work® certification in France and Mexico,
and DiversityInc Noteworthy Company. Hillrom also extended gender
diversity in the boardroom, bringing women representation to 36 percent
of the company's board of directors.
Fiscal 2021 Financial Outlook
For fiscal 2021, Hillrom expects revenue to decline 3 to 5 percent on a reported and constant currency basis. The company expects adjusted earnings of $5.25 to $5.45 per diluted share and operating cash flow of $370 to $400 million. The company expects to complete the exit of the Surgical Solutions international OEM business at the end of the 2020 calendar year, and as previously communicated, is retiring the definition of core revenue for fiscal 2021.
For the fiscal first quarter 2021, Hillrom expects revenue to decline 3 to 5 percent on a reported and constant currency basis. The company expects adjusted earnings of $1.05 to $1.10 per diluted share.
The company currently anticipates normalized demand for products that peaked during fiscal 2020 in support of COVID-19 needs, as well as a gradual recovery for other product categories that were negatively impacted. The ongoing scope and evolution of the pandemic remains uncertain and could present pandemic-related risks or opportunities that may require updates to the fiscal 2021 guidance ranges provided today.
Discussion of Adjusted Financial Measures
In addition to the results reported in accordance with accounting principles generally accepted in the United States (GAAP), Hillrom routinely provides gross margin, operating margin, income before taxes, income tax expense, and earnings per diluted share results on an adjusted basis because the company's management believes these measures contribute to an understanding of our financial performance, provide additional analytical tools to understand our results from core operations and reveal underlying operating trends. These measures exclude strategic developments, acquisition and integration costs and related fair value adjustments, gains and losses associated with disposals of businesses or significant product lines, regulatory costs related to updating existing product registrations to comply with the European Medical Device Regulations, special charges, the transitional impacts of U.S. tax reform legislation, changes in tax accounting methods, other tax law changes and expenses associated with these tax items, the impacts of significant litigation matters, certain impacts of the COVID-19 pandemic, and other unusual events. The company also excludes expenses associated with the amortization of purchased intangible assets. These adjustments are made to allow investors to evaluate and understand operating trends excluding their impact on operating income and earnings per diluted share.
Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Reconciliations of GAAP measures to adjusted measures appear in the financial tables of this release.
The company also routinely provides earnings per diluted share guidance on an adjusted basis. This excludes the impact of intangible asset amortization associated with prior business acquisitions, which we expect to be $1.27 to $1.32 per diluted share for the fiscal year 2021. Management also does not include adjusted items such as strategic developments, acquisition and integration costs, special charges, and other special items or unusual items in our guidance because such items are evaluated on an ongoing basis, can be highly variable and cannot be reasonably predicted. As such, prospective quantification of these items is not feasible, and a full reconciliation of non-GAAP earnings per diluted share guidance to GAAP earnings per diluted share has not been provided. However, as a result of acquisitions, our ongoing portfolio and business optimization initiatives, and any change to the transitional impacts from U.S. tax reform legislation, we do expect adjusted items we have not predicted to potentially be significant to our GAAP measures including gross margin, operating margin, income tax expense and earnings per diluted share.
The company also presents certain results on a constant currency basis, which compares results between periods as if foreign currency exchange rates had remained consistent period-over-period. Management monitors sales performance on an adjusted basis that eliminates the positive or negative effects that result from translating international sales into U.S. dollars. Management calculates constant currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period. Management believes that evaluating growth in net revenue on a constant currency basis provides an additional and meaningful assessment to both management and investors.
Conference Call Webcast and Dial-in Information
The company will host a conference call and webcast today beginning at 7:00 a.m. (CT) / 8:00 a.m. (ET).
Conference Call Audio Only Dial-in Information: To participate in the conference call, dial (844) 654-5620 (domestic) or (647) 253-8654 (international). Please dial into the call at least 10 minutes prior to the start to allow time to connect. The confirmation code is 7657616.
Webcast: A simultaneous webcast of the call will be accessible via the company's website at www.hillrom.com. A supplementary presentation will be posted to the Hillrom website prior to the webcast.
A recording of the webcast/call audio will be available for telephone replay for a period of 7 days following the earnings call. To access the replay, dial (800) 585-8367 (domestic) or (416) 621-4642 (international). For the replay, callers will need to use confirmation code 7657616. If you are unable to listen to the live webcast or the telephone replay, the webcast will be archived at www.hillrom.com.
About Hillrom
Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by advancing connected care. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.
Disclosure Regarding Forward-Looking Statements
Certain statements herein contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the company's future plans, proposed divestitures, product launches, objectives, beliefs, expectations, representations and projections. It is important to note that forward-looking statements are not guarantees of future performance, and the company's actual results could differ materially from those set forth in any forward-looking statements. The company's actual results also could be materially adversely impacted by the length and severity of the COVID-19 pandemic, and related impacts on the company's business, results of operations, financial condition and prospects. For a more in-depth discussion of factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the company's previously filed most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The company assumes no obligation to update or revise any forward-looking statements, unless required by law.
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED INCOME (Unaudited)
(In millions, except per share data)
Three Months Ended
Year Ended
September 30 September 30
2020 2019 2020 2019
Net Revenue
Product sales and service $
624.1 $
713.9 $
2,571.2 $
2,615.0
Rental revenue 81.2 68.9 309.8 292.3
Total net revenue 705.3 782.8 2,881.0 2,907.3
Cost of Net Revenue
Cost of goods sold 313.3 359.4 1,259.9 1,330.7
Rental expenses 35.1 37.6 146.0 151.6
Total cost of net revenue (excludes acquisition-related intangible asset amortization) 348.4 397 1,405.9 1,482.3
Research and development expenses 36.2 35.6 136.5 139.5
Selling and administrative expenses 211.5 205.3 820.4 818.6
Acquisition-related intangible asset amortization 27.7 40.1 109.0 122.4
Special charges 15.3 10.7 41.5 28.4
Operating Profit 66.2 94.1 367.7 316.1
Interest expense (18.1) (23.4) (74.0) (89.6)
Loss on extinguishment of debt (3.3) (15.6) (3.3)
Investment income (expense) and other, net 3.5 (14.8) (6.9) (14.6)
Income Before Income Taxes 51.6 52.6 271.2 208.6
Income tax expense (benefit) 9.2 24.7 48.2 56.4
Net Income $
42.4 $
27.9 $
223.0 $
152.2
Net Income per Basic Common Share $
0.64 $
0.42 $
3.35 $
2.28
Net Income per Diluted Common Share $
0.63 $
0.41 $
3.32 $
2.25
Average Basic Common Shares Outstanding (in thousands) 66,606 66.686 66,631 66.772
Average Diluted Common Shares Outstanding (in thousands) 67,181 67,572 67,212 67,660
Hill-Rom Holdings, Inc. and Subsidiaries
Revenue Constant Currency (Unaudited)
(In millions)
U.S.
OUS
Three Months Ended Change As Constant Change As Change As Constant
September 30 Reported Currency Reported Reported Currency
2020 2019
Net Revenue:
Product sales and service $
624.1 $
713.9 (12.6) (13.4) (21.1) 8.3 5.4
% % % % %
Rental revenue 81.2 68.9 17.9 17.3 20.9 (2.1) (6.3)
% % %
% %
Total net revenue $
705.3 $
782.8 (9.9)
% % % %
% (10.7) (16.7) 7.9 4.9
Net Revenue:
Patient Support Systems $
365.0 $
415.4 (12.1) (12.9) (20.7) 20.5 16.8
% % % % %
Front Line Care 260.0 257.2 1.1 0.7 (1.8)
% % % %
% 8.6 7.3
Surgical Solutions 80.3 110.2 (27.1) (29.4) (45.0) (11.4) (15.7)
% % % % %
Total net revenue $
705.3 $
782.8 (9.9)
% % % %
% (10.7) (16.7) 7.9 4.9
OUS - Outside of the United States
U.S.
OUS
Year Ended September 30 Change As Constant Change As Change As Constant
Reported Currency Reported Reported Currency
2020 2019
Net Revenue:
Product sales and service $
2,571.2 $
2,615.0 (1.7) (1.3) (6.0)
% %
% % % 8.0 9.3
Rental revenue 309.8 292.3 6.0 6.1 7.4 (3.1) (2.5)
% % %
% %
Total net revenue $
2,881.0 $
2,907.3 (0.9) (0.5) (4.4)
% %
% % % 7.5 8.7
Net Revenue:
Patient Support Systems $
1,539.1 $
1,490.5 3.3 3.6 (0.1)
% % % %
% 14.1 15.6
Front Line Care 1,025.0 978.1 4.8 5.2 1.0 14.4 16.0
% % % % %
Surgical Solutions 316.9 438.7 (27.8) (27.6) (43.1) (12.1) (11.9)
% % % % %
Total net revenue $
2,881.0 $
2,907.3 (0.9) (0.5) (4.4)
% %
% % % 7.5 8.7
Hill-Rom Holdings, Inc. and Subsidiaries
Reconciliation: Earnings Per Share (Unaudited)
(In millions, except per share data)
Three Months Ended September 30, 2020
Three Months Ended September 30, 2019
---
Operating Income Income Tax Diluted Operating Income Income Tax Diluted
Margin Before Expense EPS Margin Before Expense EPS
Income Income
Taxes Taxes
---
GAAP Basis 9.4
%
% $
51.6 $
9.2 $
0.63 12.0 $
52.6 $
24.7 $
0.41
Adjustments:
Acquisition and integration costs and related fair value 0.3
%
% 2.0 0.4 0.03 1.6 12.4 2.1 0.15
adjustments
Acquisition-related intangible asset amortization 3.9
%
% 27.7 6.4 0.32 5.1 40.1 8.9 0.46
Field corrective actions 0.4
% 2.8 0.6 0.03 %
Regulatory compliance costs 0.4
%
% 2.8 0.7 0.03 0.6 4.6 0.9 0.05
Special charges 2.2
%
% 15.3 3.1 0.18 1.4 10.7 2.6 0.12
Tax law and method changes - % % (0.4) 0.01
Debt refinancing costs - % % 4.0 0.9 0.05
(Gain) loss on business combinations - % (2.9) (0.3) (0.04) % 15.9 (12.4) 0.42
Litigation expenses and awards - % 0.2
% 2.0 0.5 0.02
COVID-19 related costs and benefits, net (0.1)
% (0.5) (0.1) (0.01) %
16.5
%
Adjusted Basis % $
98.8 $
20.0 $
1.17 20.9 $
142.3 $
27.8 $
1.69
Year Ended September 30, 2020
Year Ended September 30, 2019
---
Operating Income Income Tax Diluted Operating Income Income Tax Diluted
Margin Before Expense EPS Margin Before Expense EPS
Income Income
Taxes Taxes
---
12.8
%
GAAP Basis % $
271.2 $
48.2 $
3.32 10.9 $
208.6 $
56.4 $
2.25
Adjustments:
Acquisition and integration costs and related fair value - % (0.6) 1.8 (0.04) 0.9
% 28.1 5.3 0.34
adjustments
Acquisition-related intangible asset amortization 3.7
%
% 109.0 26.1 1.23 4.2 122.4 28.6 1.38
Field corrective actions 0.2
%
% 4.9 1.2 0.05 0.2 5.6 1.4 0.06
Regulatory compliance costs 0.5
%
% 15.6 3.7 0.18 0.5 15.3 3.6 0.17
Special charges 1.4
%
% 41.5 9.2 0.48 1.0 28.4 6.9 0.32
Tax law and method changes - % % (4.8) 0.07
Debt refinancing costs - % 16.1 3.7 0.18 % 4.0 0.9 0.05
(Gain) loss on business combinations - % (2.8) (4.4) 0.02 % 15.9 (12.4) 0.42
Pension settlement expense - % 8.4 1.9 0.10 %
Litigation expenses and awards - % (1.2) (0.3) (0.01) 0.1
% 2.0 0.5 0.02
COVID-19 related costs and benefits, net 0.2
% 1.4 0.7 0.02 %
18.8
%
Adjusted Basis % $
463.5 $
91.8 $
5.53 17.8 $
430.3 $
86.4 $
5.08
Hill-Rom Holdings, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS (Unaudited)
(In millions, except share amounts)
September 30, September 30,
2020 2019
---
ASSETS
Current Assets
Cash and cash equivalents $
296.5 $
214.1
Restricted cash - 419.7
Trade accounts receivable, net of allowances of $25.9 and $20.6 in fiscal 2020 and 2019 594.9 653.3
Inventories, net of reserves of $73.0 and $57.3 in fiscal 2020 and 2019 352.0 269.6
Other current assets 121.5 106.7
Total current assets 1,364.9 1,663.4
Property, plant and equipment 858.2 829.6
Less accumulated depreciation (552.1) (532.8)
Property, plant and equipment, net 306.1 296.8
Goodwill 1,835.5 1,800.9
Other intangible assets and software, net 976.7 1,033.5
Deferred income taxes 32.9 33.1
Other assets 155.0 91.3
Total Assets $
4,671.1 $
4,919.0
LIABILITIES
Current Liabilities
Trade accounts payable $
236.5 $
197.6
Short-term borrowings 222.3 660.4
Accrued compensation 144.9 130.4
Accrued product warranties 30.8 29.7
Accrued rebates 44.8 47.7
Deferred revenue 110.1 107.3
Other current liabilities 162.8 95.2
Total current liabilities 952.2 1,268.3
Long-term debt 1,655.7 1,783.1
Accrued pension and postretirement benefits 89.3 80.8
Deferred income taxes 113.0 143.0
Other long-term liabilities 134.8 70.5
Total Liabilities 2,945.0 3,345.7
Commitments and Contingencies
SHAREHOLDERS' EQUITY
Capital Stock:
Preferred stock - without par value: Authorized - 1,000,000; none issued or outstanding
Common stock - without par value: Authorized - 199,000,000 4.4 4.4
Issued: 88,457,634 shares as of September 30, 2020 and September 30, 2019; Outstanding: 66,640,832 as of
September 30, 2020 and 66,625,011 as of September 30, 2019
Additional paid-in capital 667.0 637.4
Retained earnings 2,132.2 1,967.4
Accumulated other comprehensive income (loss) (180.2) (182.5)
Treasury stock, common shares at cost: 21,816,802 as of September 30, 2020 and 21,832,623 as of September (897.3) (853.4)
30, 2019
Total Shareholders' Equity 1,726.1 1,573.3
Total Liabilities and Shareholders' Equity $
4,671.1 $
4,919.0
Hill-Rom Holdings, Inc. and Subsidiaries
STATEMENTS OF CONSOLIDATED CASH FLOWS (Unaudited)
(In millions)
Year Ended September 30
2020 2019
Operating Activities
Net income $
223.0 $
152.2
Adjustments to reconcile net income to net cash, cash equivalents and restricted cash provided by operating
activities:
Depreciation and amortization of property, plant, equipment and software 69.8 72.4
Acquisition-related intangible asset amortization 109.0 122.4
Amortization of debt discounts and issuance costs 4.0 7.1
Loss on extinguishment of debt 15.6 3.0
Benefit for deferred income taxes (19.0) (18.8)
Loss on disposal of property, equipment, intangible assets, and impairments 2.7 3.4
Stock compensation 38.4 34.4
Other operating activities 27.1 28.3
Change in working capital excluding cash, current debt, acquisitions and dispositions:
Trade accounts receivable 71.3 (62.3)
Inventories (91.8) (0.9)
Other current assets (14.8) 15.7
Trade accounts payable 24.0 13.2
Accrued expenses and other liabilities 15.4 28.8
Other assets and liabilities 7.0 2.5
Net cash, cash equivalents and restricted cash provided by operating activities 481.7 401.4
Investing Activities
Purchases of property, plant, equipment and software (105.9) (73.4)
Proceeds on sale of property and equipment 2.5 2.9
Payment for acquisition of businesses, net of cash acquired (28.4) (303.4)
Payments for acquisition of intangible assets (17.1)
Payments for acquisition of investments (26.6)
Proceeds on sale of businesses 0.8 166.6
Other investing activities (0.2) 2.0
Net cash, cash equivalents and restricted cash used in investing activities (131.2) (249.0)
Financing Activities
Proceeds from borrowing on long-term debt 1,000.0
Payments of long-term debt (50.1) (1,038.5)
Borrowings on Revolving Credit Facility 190.0 420.0
Payments on Revolving Credit Facility (270.0) (340.0)
Borrowings on Securitization Facility 17.7 5.5
Payments on Securitization Facility (45.5) (5.5)
Borrowings on Note Securitization Facility 32.6 68.9
Payments on Note Securitization Facility (21.2) (62.7)
Proceeds from issuance of senior unsecured notes 425.0
Payment of debt issuance costs (12.7)
Prepayment premium on extinguishment of 5.75% Notes (12.2)
Redemption of 5.75% Notes (425.0)
Cash dividends (58.0) (55.4)
Proceeds on exercise of stock options 8.6 14.5
Stock repurchases for stock award withholding obligations (16.5) (4.7)
Stock repurchases in the open market (54.1) (117.2)
Other financing activities 8.7 7.5
Net cash, cash equivalents and restricted cash (used in) provided by financing activities (695.0) 304.7
Effect of exchange rate changes on cash, cash equivalents and restricted cash 7.2 (6.3)
Net Cash Flows (337.3) 450.8
Cash, Cash Equivalents and Restricted Cash:
At beginning of period 633.8 183.0
At end of period $
296.5 $
633.8
CONTACT INFORMATION
Investor Relations
---
Contact:
Mary Kay Ladone, Senior Vice
Contact:
Lorna Williams, Executive Director,
President, Corporate Development,
Phone:
Investor Relations and Strategy
Strategy and Investor Relations 312-233-7799
Phone:
312-819-9387
Email:
lorna.williams@hillrom.com
Email:
marykay.ladone@hillrom.com
Media
---
Contact:
Howard Karesh, Vice President, Corporate Communications
Phone:
312-819-7268
Email:
howard.karesh@hillrom.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/hillrom-reports-fiscal-fourth-quarter-and-full-year-2020-financial-results-301167682.html
SOURCE Hillrom
